PNC Financial Services Group’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-252
| Closed | -$421 | – | 5250 |
|
|
2025
Q4 | $421 | Sell |
252
-145
| -37% | -$251 | ﹤0.01% | 4878 |
|
|
2025
Q3 | $671 | Sell |
397
-4
| -1% | -$5 | ﹤0.01% | 4754 |
|
|
2025
Q2 | $364 | Buy |
401
+355
| +772% | +$211 | ﹤0.01% | 4724 |
|
|
2025
Q1 | $21 | Buy |
46
+38
| +475% | +$22 | ﹤0.01% | 4864 |
|
|
2024
Q4 | $4 | Buy |
+8
| New | +$6 | ﹤0.01% | 4775 |
|
|
2024
Q1 | – | Sell |
-180
| Closed | -$196 | – | 4763 |
|
|
2023
Q4 | $196 | Buy |
+180
| New | +$197 | ﹤0.01% | 4491 |
|
|
2020
Q3 | – | Sell |
-300
| Closed | – | – | 3981 |
|
|
2020
Q2 | $0 | Hold |
300
| – | – | ﹤0.01% | 3986 |
|
|
2020
Q1 | $0 | Hold |
300
| – | – | ﹤0.01% | 3980 |
|
|
2019
Q4 | $0 | Hold |
300
| – | – | ﹤0.01% | 4049 |
|
|
2019
Q3 | $0 | Sell |
300
-10
| -3% | -$10 | ﹤0.01% | 4059 |
|
|
2019
Q2 | $0 | Buy |
310
+10
| +3% | +$12 | ﹤0.01% | 4081 |
|
|
2019
Q1 | $0 | Hold |
300
| – | – | ﹤0.01% | 4084 |
|
|
2018
Q4 | $0 | Sell |
300
-43
| -13% | -$66 | ﹤0.01% | 4112 |
|
|
2018
Q3 | $0 | Hold |
343
| – | – | ﹤0.01% | 4186 |
|
|
2018
Q2 | $0 | Hold |
343
| – | – | ﹤0.01% | 4210 |
|
|
2018
Q1 | $0 | Hold |
343
| – | – | ﹤0.01% | 4234 |
|
|
2017
Q4 | $0 | Hold |
343
| – | – | ﹤0.01% | 4192 |
|
|
2017
Q3 | $0 | Sell |
343
-91,440
| -100% | -$227K | ﹤0.01% | 4186 |
|
|
2017
Q2 | $252K | Hold |
91,783
| – | – | ﹤0.01% | 2009 |
|
|
2017
Q1 | $278K | Hold |
91,783
| – | – | ﹤0.01% | 1947 |
|
|
2016
Q4 | $290K | Hold |
91,783
| – | – | ﹤0.01% | 1908 |
|
|
2016
Q3 | $314K | Hold |
91,783
| – | – | ﹤0.01% | 1831 |
|
|
2016
Q2 | $210K | Hold |
91,783
| – | – | ﹤0.01% | 2048 |
|
|
2016
Q1 | $230K | Sell |
91,783
-7,710
| -8% | -$17.2K | ﹤0.01% | 2018 |
|
|
2015
Q4 | $330K | Buy |
99,493
+12,390
| +14% | +$37K | ﹤0.01% | 1762 |
|
|
2015
Q3 | $210K | Buy |
87,103
+372
| +0.4% | +$963 | ﹤0.01% | 2084 |
|
|
2015
Q2 | $254K | Hold |
86,731
| – | – | ﹤0.01% | 2063 |
|
|
2015
Q1 | $348K | Buy |
86,731
+24,780
| +40% | +$85.7K | ﹤0.01% | 1877 |
|
|
2014
Q4 | $186K | Hold |
61,951
| – | – | ﹤0.01% | 2120 |
|
|
2014
Q3 | $158K | Buy |
+61,951
| New | +$149K | ﹤0.01% | 2133 |
|
Other funds holding LCTX
BC
DC
RA
AC
PNC Financial Services Group's LCTX Position: Q1 2026 in Review
PNC Financial Services Group sold out of Lineage Cell Therapeutics (LCTX) in Q1 2026, closing a stake of 252 shares — an estimated $421 sold.
PNC Financial Services Group first reported a position in LCTX in Q3 2014 and held it in 30 quarters. The position peaked at $348K in Q1 2015. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.
- PNC Financial Services Group reported no remaining Lineage Cell Therapeutics position as of Q1 2026 after selling out during the quarter.
- PNC Financial Services Group sold 252 Lineage Cell Therapeutics shares in Q1 2026, an estimated $421.
- PNC Financial Services Group first reported a position in Lineage Cell Therapeutics in Q3 2014 and held it in 30 quarters.
- PNC Financial Services Group's Lineage Cell Therapeutics position peaked at $348K in Q1 2015.
- 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.
Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.